Kaveri Pohlman
Stock Analyst at Clear Street
(1.71)
# 3,396
Out of 5,090 analysts
29
Total ratings
30%
Success rate
-5.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $80 → $32 | $16.38 | +95.36% | 2 | Dec 2, 2025 | |
| JBIO Jade Biosciences | Initiates: Buy | $25 | $12.52 | +99.76% | 1 | Nov 25, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $11 → $21 | $13.57 | +54.81% | 1 | Nov 14, 2025 | |
| ZURA Zura Bio | Initiates: Buy | $18 | $3.87 | +365.12% | 1 | Nov 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $29 | $6.37 | +355.26% | 1 | Oct 22, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $41 → $60 | $34.40 | +74.42% | 2 | Oct 21, 2025 | |
| VTYX Ventyx Biosciences | Initiates: Buy | $11 | $7.99 | +37.67% | 1 | Oct 1, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $46 | $30.94 | +48.67% | 1 | Sep 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $24.21 | +32.18% | 1 | Jun 25, 2025 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.38 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $47 | $32.03 | +46.74% | 3 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $30 | $10.59 | +183.29% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $38 | $18.05 | +110.53% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $8.31 | -39.83% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.37 | +83.28% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $44.40 | -39.18% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $25.26 | +177.12% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.99 | +301.34% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $4.09 | +95.60% | 2 | Jul 7, 2022 |
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $80 → $32
Current: $16.38
Upside: +95.36%
Jade Biosciences
Nov 25, 2025
Initiates: Buy
Price Target: $25
Current: $12.52
Upside: +99.76%
Trevi Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $11 → $21
Current: $13.57
Upside: +54.81%
Zura Bio
Nov 13, 2025
Initiates: Buy
Price Target: $18
Current: $3.87
Upside: +365.12%
Sagimet Biosciences
Oct 22, 2025
Initiates: Buy
Price Target: $29
Current: $6.37
Upside: +355.26%
RAPT Therapeutics
Oct 21, 2025
Maintains: Buy
Price Target: $41 → $60
Current: $34.40
Upside: +74.42%
Ventyx Biosciences
Oct 1, 2025
Initiates: Buy
Price Target: $11
Current: $7.99
Upside: +37.67%
Oruka Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $30.94
Upside: +48.67%
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $24.21
Upside: +32.18%
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $32.03
Upside: +46.74%
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $10.59
Upside: +183.29%
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $18.05
Upside: +110.53%
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $8.31
Upside: -39.83%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $4.37
Upside: +83.28%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $44.40
Upside: -39.18%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $25.26
Upside: +177.12%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $2.99
Upside: +301.34%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $4.09
Upside: +95.60%